行情

CRVS

CRVS

Corvus制药
NASDAQ

实时行情|Nasdaq Last Sale

4.250
-0.080
-1.85%
休市 16:00 08/07 EDT
开盘
4.350
昨收
4.330
最高
4.420
最低
4.170
成交量
17.68万
成交额
--
52周最高
6.88
52周最低
1.010
市值
1.19亿
市盈率(TTM)
-2.7411
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CRVS价格均价为9.20,最高价位15.00,最低价为6.00。

EPS

CRVS 新闻

更多
Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
BURLINGAME, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will
GlobeNewswire · 3天前
Corvus Pharmaceuticals Q2 EPS $(0.36) Misses $(0.28) Estimate
Corvus Pharmaceuticals (NASDAQ:CRVS) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 18.18 percent increase over losses of $(0.44) per
Benzinga · 07/30 20:05
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
Provides Update on CPI-006 Phase 1 COVID-19 Study Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provide
GlobeNewswire · 07/30 20:02
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
CBAY, TEAM, MDRX and SHAK among after-hours movers
Seeking Alpha · 07/30 04:00
Corvus Pharmaceuticals EPS misses by $0.06
Seeking Alpha · 07/30 04:00
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a co
GlobeNewswire · 07/23 12:30
3 “Strong Buy” Healthcare Stocks Under $5 That Could Double (Or More)
The healthcare sector took its place among the winners this year, rising 21%, compared to the S&P 500’s 0.5% growth. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking in on biotechs in particular.It should be noted that the
TipRanks · 07/20 19:30

所属板块

生物技术和医学研究
-0.18%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

CRVS 简况

Corvus Pharmaceuticals, Inc.是一家临床阶段的生物制药公司。该公司专注于免疫肿瘤治疗的开发与销售业务。该公司正在开发阻断关键免疫检查点和重编程免疫T细胞的药物和抗体。该公司拥有四个免疫肿瘤学项目,其中三个专注于腺苷癌轴调节免疫反应。该公司的主要候选产品CPI-444是一种用于腺苷A2A受体(一个免疫检查点)的口服小分子拮抗剂。该公司的其他产品包括腺苷产生抑制剂(单克隆抗CD73抗体)、腺苷A2B拮抗剂和诱导性白细胞介素-2(IL-2)T细胞激酶(ITK)抑制剂。截至2016年9月30日,该公司未产生收入。
展开

微牛提供Corvus Pharmaceuticals Inc(NASDAQ-CRVS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CRVS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CRVS股票基本功能。